Guidelines for HER2 testing in the UK.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Observer performance in the use of digital and optical microscopy for the interpretation of tissue-based biomarkers.Analytical cellular pathology (Amsterdam) · 2014
   Article
2. External Quality Assessment (EQA) program for the preanalytical and analytical immunohistochemical determination of HER2 in breast cancer: an experience on a regional scale.Journal of experimental & clinical cancer research : CR · 2013
   Article
3. Multiparameter DNA content analysis identifies distinct groups in primary breast cancer.British journal of cancer · 2013
   Article
4. p16 expression correlates with basal-like triple-negative breast carcinoma.Ecancermedicalscience · 2013
   Article
5. Image analysis as an adjunct to manual HER-2 immunohistochemical review: a diagnostic tool to standardize interpretation.Histopathology · 2010
   Article
6. Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens.Pathology research international · 2010
   Article
7. Virtual microscopy as an enabler of automated/quantitative assessment of protein expression in TMAs.Histochemistry and cell biology · 2008
   Review
8. Serum HER-2 concentration in patients with primary breast cancer.Journal of clinical pathology · 2006
   Article
9. Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma.Journal of clinical pathology · 2005
   Article

Corrections and comments

• Comment on
  Best Practice No 176: Updated recommendations for HER2 testing in the UK.2004

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as